|
J Biol Chem, Vol. 275, Issue 1, 177-181, January 7, 2000
N-Acylated Serinol Is a Novel Ceramide Mimic
Inducing Apoptosis in Neuroblastoma Cells*
Erhard
Bieberich ,
Takahisa
Kawaguchi, and
Robert K.
Yu
From the Department of Biochemistry and Molecular Biochemistry,
Medical College of Virginia Campus of Virginia Commonwealth University,
Richmond, Virginia 23298-0614
 |
ABSTRACT |
A novel structural analog of ceramide was
synthesized by N-acylation of serinol
(2-amino-1,3-propanediol) and studied for its effects on glycolipid
biosynthesis and cell differentiation of neuroblastoma cells.
Incubation with N-palmitoylated serinol (C16-serinol)
increased the concentration of endogenous ceramide by 50-80% and
caused apoptosis in rapidly dividing low density cells but not in
confluent cells. Cell death was not suppressed by simultaneous
incubation with phorbol ester, known to antagonize ceramide-induced
apoptosis by activation of protein kinase C (PKC). Purification of
potential target proteins of C16-serinol was achieved by affinity
chromatography of a protein preparation from rat brain on immobilized
C16-serinol. A gel activity assay revealed that the eluate from
C16-serinol-Sepharose contained three serine/threonine-specific protein
kinases with molecular masses of 50, 70, and 95 kDa. The 70-kDa protein
was immunostained on a Western blot using a PKC -specific antibody.
The purified PKC could be activated directly by C16-serinol in an
in vitro phosphorylation assay. Induction of apoptosis in neuroblastoma cells was suppressed by inhibition of PKC with Gö 6983. Our overall results indicate that apoptosis in
neuroblastoma cells induced by C16-serinol was at least partially
mediated by activation of PKC on condition of ongoing cell division.
N-Acylated serinols may thus be useful for induction of
apoptosis in mitotic cells and may be of therapeutic potential for
treatment of cancer in the nervous system.
 |
INTRODUCTION |
Sphingosine and its N-acylated derivative, ceramide,
are important lipid second messengers for regulation of cell growth and apoptosis and entry substrates for the generation of phospho- and
glycosphingolipids (1-11). In particular, apoptosis is known to be
induced by elevation of endogenous ceramide or sphingosine (1-10).
Structural analogs of these two compounds are expected to target
sphingolipid-binding enzymes specifically, by acting as potential
inhibitors or allosteric effectors. Commercially available ceramide
analogs are either inhibitors of glycosphingolipid biosynthesis or
ceramide degradation, giving rise to an elevation of endogenous
ceramide. PDMP1 and related
derivatives are known to inhibit UDP-glucose:ceramide glucosyltransferase (hereafter glucosyltransferase), whereas
d-erythro-MAPP and NOE are used for inhibition of ceramidase
(12-17). It has been shown that several of these inhibitors may induce
apoptosis by mechanisms other than elevation of endogenous ceramide
(18). However, a direct binding to distinct proteins involved in
regulation of apoptosis has not been demonstrated yet. The rational
design of novel ceramide analogs was expected to facilitate the
analysis of the structure/function relationship of ceramide analogs and the physiological activity of ceramide itself. Fig.
1 shows the structure of
N-palmitoylated serinol (C16-serinol), which is derived from
N-acylation of a -hydroxyamide motif that serves as a
common structural element in the sphingoid base and almost all
effectors of glucosyltransferase or ceramidase. The contribution of a
second -hydroxymethyl group in C16-serinol was evaluated by
comparison with the effects of N-palmitoylethanolamine
(C16-EA) on neuroblastoma cells. The activity of the new compounds was
analyzed by their ability to affect sphingolipid metabolism and
cellular differentiation, in particular apoptosis, and by their
potential to bind directly to proteins prepared from neuronal cells or
tissues. We will present an experimental approach for analyzing
potential binding proteins of ceramide or its analogs by utilizing
C16-serinol as an immobilized ligand for affinity chromatography
purification of proteins from rat brain tissue.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Murine neuroblastoma × rat glioma NG108-15
and murine neurobastoma × rat dorsal root ganglion F-11 cells
were kindly provided by Drs. Robert Ledeen (New Jersey School of
Medicine, Newark, NJ) and Glyn Dawson (University of Chicago, Chicago,
IL), respectively. PC12 (rat adrenal pheochromocytoma, ATCC CRL 1721)
cells were purchased from the American Tissue Culture Collection
(Rockville, MD). Culture dishes were from Falcon/Becton Dickinson Co.
(Franklin Lakes, NJ). Serinol (2-amino-1,3-propanediol),
octanoylchloride, palmitoylchloride, and stearoylchloride were
purchased from Across/Fisher Scientific (Pittsburgh, PA). Ceramide,
glucosylceramide, C16-EA, and NOE were from Matreya (Pleasant Gap, PA).
Dulbecco's modified Eagle's medium was obtained from Life
Technologies, Inc. Ceramide standards, phosphatidylethanolamine,
phosphatidylserine, dioctanoylglycerol, N-palmitoylsphingosine, -phorbol 12-myristate 13-acetate
(PMA), forskolin, rabbit polyclonal anti-PKC antibody, protein
A-Sepharose, bovine brain myelin basic protein, and Hoechst dye 33258 were purchased from Sigma. Carrier-free 32P (9,000 Ci/mmol)
and [ -32P]ATP (6,000 Ci/mmol) were from NEN Life
Science Products. UDP-[14C]glucose (286 mCi/mmol) was
from ICN Pharmaceuticals (Costa Mesa, CA). A polyclonal rabbit IgG
anti-cyclin E antibody was from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA) and goat anti-rabbit IgG-rhodamine conjugate from Jackson
ImmunoResearch (West Grove, PA). High performance TLC (HPTLC) plates
were from Merck (Darmstadt, Germany). All other chemicals were of
analytical grade or higher, and solvents were freshly redistilled
before use.
Analysis of Lipid Composition and Metabolic
Enzymes--
NG108-15 and F-11 cells were propagated in Dulbecco's
modified Eagle's medium supplemented with 10% fetal bovine serum in a
humidified atmosphere at 5% CO2. Alternatively, cells were
incubated for 12-72 h with different concentrations of
N-acylated serinol, N-palmitoyl or
N-oleoylethanolamine, or PMA as indicated under "Results." For lipid extraction, protein determination, DNA
laddering, or enzyme assays, cells were harvested by scraping and
pelleted by centrifugation at 300 × g for 5 min.
Lipids were prepared and analyzed by HPTLC as described previously
(19). HPTLC for ceramide was developed in CHCl3/HOAc (9:1,
v/v), and staining was performed with 3% cupric acetate in 8%
phosphoric acid as described elsewhere (20, 21). Glycolipids and
sphingomyelin were prepared and analyzed as described previously (22,
23). The activity of glucosyltransferase was analyzed with
UDP-[14C]glucose and ceramide or C16-serinol used as
substrate, and with cell or rat brain homogenate as enzyme source
following a procedure described elsewhere (24). The activity of
ceramidase was determined with a lysosomal preparation from rat brain
as described in Ref. 25 with modifications. Product lipids were
separated by HPTLC and quantified by autoradiography or staining
followed by densitometric analysis.
Synthesis of N-Acylated Serinol and C16-Serinol Affinity
Gel--
C16-serinol was synthesized from a solution of 50 mg (549 µmol) of 2-amino-1,3-propanediol in 15 ml of pyridine supplemented with 1.65 mmol (457 µl) of palmitoylchloride at 30 °C. The
reaction mixture was stirred for 2 h at room temperature followed
by the addition of 30 ml of CH3OH. After stirring for
another 2 h at room temperature the reaction product was
concentrated by evaporation. For selective hydrolysis of the ester
group, the concentrate was supplemented with 30 ml of CH3OH
and sodium methoxide (pH 11-12) and stirred for 2 h at room
temperature. The mixture was neutralized and concentrated. The reaction
product was purified by chromatography on a silica gel column (5 g)
with CHCl3/CH3OH (5:1, v/v) as the running
solvent. The yield of C16-serinol was 75% (135 mg). The purity and
structure were verified by NMR and mass spectrometry. C16-serinol was
found to be soluble at a concentration of up to 500 µM in
aqueous solution. For optimal solubility sodium stearate was added to
the solution at 20% of the concentration of C16-serinol. The octanoyl
and stearoyl derivative of serinol (C8-, C18-serinol) were synthesized
following the same procedure used for the synthesis of C16-serinol.
C16-serinol-Sepharose was synthesized as follows. Octyl Sepharose 4B,
fast flow (Amersham Pharmacia Biotech), 2 ml, was washed three times
with 10 ml of CH3OH/0.1 M KCl (1:1, v/v) and
then three times with 10 ml of solvent A
(CHCl3/CH3OH/H2O, 30:60:8, v/v/v).
The Sepharose gel (2 ml) was supplemented with 2 ml of solvent A
containing 4 mg of C16-serinol and incubated for 30 min at room
temperature. The gel was washed with 10 ml of
CH3OH/phosphate-buffered saline (1:1, v/v) and 10 ml of
phosphate-buffered saline before use.
Affinity Purification of Rat Brain Protein on
C16-Serinol-Sepharose--
2 g of rat brain was solubilized with 10 ml
of 50 mM Hepes buffer, pH 7.0, supplemented with 0.5 M NaCl, 0.5% Triton X-100, 1 mM
-mercaptoethanol, 250 µM phenylmethylsulfonyl
fluoride, and 1 µg/ml leupeptin, pepstatin, aprotinin by five strokes
with a Teflon-glass homogenizer at 2,500 rpm. The solubilized protein was first incubated for 1 h at 4 °C and then any insoluble
material removed by centrifugation at 60,000 × g for
1 h using a Beckman SW50.1 rotor. The supernatant was diluted 1:30
with Hepes buffer omitting Triton X-100 and centrifuged again for 60 min at 60,000 × g. The resulting supernatant was then
incubated with 1.0 ml of C16-serinol-Sepharose and incubated for 2 h (or overnight) at 4 °C. The gel was washed in a column with 100 volumes of Hepes buffer without Triton X-100 and then eluted with 1 ml
of buffer or 0.5 mM C16-serinol in buffer for 2 h at
4 °C. The protein in the elution fractions was precipitated and
analyzed by SDS-PAGE and immunoblotting or renatured in a
polyacrylamide gel and used for a gel activity assay.
Gel Activity Assay of Protein Kinases and in Vitro
Phosphorylation of PKC --
Protein eluted from
C16-serinol-Sepharose was precipitated following the
Wessel-Flügge method and the pelleted protein resolubilized by
boiling with SDS-sample buffer. An amount of 30 µg of protein affinity-purified from 1 g of rat brain was separated by SDS-PAGE. Renaturation and assay of serine/threonine protein kinases were performed according to the method of Kameshita and Fujisawa (24) as
modified by Mangoura and Dawson (27).
The in vitro phosphorylation assay was initiated by adding
10 ng of human recombinant PKC to 100 µl of a reaction mixture consisting of 25 mM Tris-HCl, pH 7.5, supplemented with 5 mM MgCl2, 0.5 mM EGTA, 1 mM dithiothreitol, 0.1 mg/ml PKC / substrate peptide, 0.1 mM ATP, and 10 µCi of [ -32P]ATP.
Alternatively, the reaction mixture was supplemented with 0.1 mg/ml
phosphatidylserine for full activation of the enzyme and various
concentrations of C16-serinol. After incubation for 15 min at 37 °C,
the reaction was stopped by the addition of 10 µl of 5% phosphoric
acid and incubated on ice for 5 min. The transferred radioactivity was
determined by binding of the substrate peptide to phosphocellulose
membranes according to the manufacturer's procedure for the use of
microcentrifuge columns (Pierce).
Autophosphorylation of PKC was analyzed by metabolic labeling of
F-11 cells with 250 µCi of 32P for 2 h at 37 °C.
Cells were plated at 50% confluence on 100-mm-diameter tissue culture
dishes with or without incubation with 100 µM C16-serinol for 8 h. The labeled cells were harvested by cell scraping and pelleted by centrifugation at 1,000 × g for 5 min.
After washing three times with 1 ml of phosphate-buffered saline, the
cells were solubilized in 500 µl of 1% Triton X-100 in 10 mM Tris-HCl, pH 7.0, supplemented with 0.2 M
NaCl, 1 µM okadaic acid, 100 µM phenylmethylsulfonyl fluoride, and 1 µg/ml leupeptin, pepstatin, and
aprotinin by incubation on ice for 10 min. The solubilized protein was
centrifuged at 14,000 × g for 10 min and the resulting supernatant incubated for 2 h at 4 °C with 10 µl of a
polyclonal anti-PKC antibody. 30 µl of protein A-Sepharose was
added to each sample, and binding of the antibody-antigen complex
proceeded for another 2 h at 4 °C. The immunocomplex was
precipitated by centrifugation at 1,000 × g for 5 min
and the immunoprecipitate washed five times with 1 ml of solubilization
buffer. The washed immunocomplex was then resolubilized by boiling for
5 min in 100 µl of SDS-sample buffer and each sample analyzed by
SDS-PAGE and autoradiography.
Analysis of Apoptosis and General Methods--
Apoptosis was
analyzed by DNA fragmentation, in situ terminal nucleotidyl
transferase assay, and staining of condensed chromatin with Hoechst dye
33258 as described elsewhere (9, 18). The degree of cell death was
monitored by determination of the number of floating cells and cells
stained with 0.4% trypan blue (28). The amount of protein was
determined according to a modification of the Folin phenol reagent
assay as described elsewhere (29). Protein precipitation was performed
according to Wessel and Flügge (30). SDS-PAGE was performed using
the Laemmli method (31), and immunoblotting followed the procedure
described by Gershoni and Palade (32).
 |
RESULTS |
Analysis of Sphingolipid Metabolism upon Incubation with
C16-Serinol--
Murine neuroblastoma NG108-15 or F-11 cells were
incubated with C16-serinol and the sphingolipid composition analyzed by
HPTLC. In particular, the levels of ceramide, sphingomyelin, and
neutral glycosphingolipids were determined by densitometric analysis
and comparison with various amounts of standard lipids. There was no
detectable alteration of the glycosphingolipid composition or the level
of sphingomyelin upon incubation with 100 µM C16-serinol. As shown in Fig. 2, incubation with
C16-serinol, however, elevated the concentration of ceramide in F-11
and NG108-15 cells with 20% confluence (lane 3, NG108-15;
lane 7, F-11) by about 50-80%. Incubation of 100%
confluent cells showed no significant alteration of endogenous ceramide
(lane 4, NG108-15; lane 8, F-11).

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 2.
Alteration of ceramide levels in
neuroblastoma cells upon incubation with C16-serinol. NG108-15 or
F-11 cells were incubated with 100 µM C16-serinol
overnight and endogenous ceramide analyzed by HPTLC of neutral lipids
corresponding to 200 µg of cellular protein applied per lane. The
HPTLC plate was developed in CHCl3/HOAc (9:1, v/v) and
sphingolipids stained with the cupric acetate/phosphoric acid reagent.
Lanes 1 and 2, control NG108-15 cells without
effector incubation, 20% (1) or 100% (2)
confluence, respectively; lanes 3 and 4, NG108-15
cells with effector incubation, 20% (3) or 100%
(4) confluence, respectively; lanes 5 and
6, control F-11 cells without effector incubation, 20%
(5) or 100% (6) confluence, respectively;
lanes 7 and 8, F-11 cells with effector
incubation, 20% (7) or 100% (8) confluence,
respectively; lane 9, standard non-hydroxyceramide;
lane 10, standard ganglioside mixture.
|
|
C16-serinol was studied for its potential as an inhibitor or substrate
for glucosyltransferase and acid ceramidase as determined with the
solubilized enzymes from rat brain using different substrate and analog
concentrations. The Km value for glucosyltransferase determined with ceramide as substrate was found to be 52 µM. The C16-serinol showed almost no inhibition of the
enzyme; however, it was accepted as a substrate for the glucosylation
reaction with a Km value of 0.8 mM. The
synthesis of glucosylated C16-serinol was analyzed by HPTLC of the
radiolabeled product and proceeded with a 10 times lower rate than that
of glucosylceramide synthesis. A potential inhibition of ceramidase
from rat brain lysosomes was analyzed with N-palmitoyl
sphingosine at 150 µM corresponding to the
Km value of the enzyme as described in literature
(26). It was found that 500 µM C16-serinol inhibited the
enzyme from rat brain by 50%, indicating that it is only a moderate
inhibitor of ceramidase.
Analysis of Cell Growth and Apoptosis--
The effect of
incubation of neuroblastoma cells with N-acylated serinols
on cell growth and development was evaluated by determination of cell
number and apoptosis. Treatment of subconfluent F-11 cells with 100 µM C16-serinol resulted in the cell death of the entire culture within 25-30 h of incubation. Cell death was concomitant with
clear morphological indications of apoptosis, e.g. blebbing of the plasma membrane. In situ detection of apoptosis using
an assay system with terminal nucleotidyl transferase revealed that about 50-60% of the NG108-15 or F-11 cells were apoptotic if cells were up to 50% confluent. Fig. 3 shows
the dependence of the number of apoptotic cells on the density of the
cells incubated with C16-serinol. It can be seen that the degree of
apoptosis was decreased markedly when cell density was below 20% or
above 50% confluence. This was confirmed by determination of cell
density-dependent DNA fragmentation (laddering) upon
incubation with 100 µM C16-serinol for 15 h. As
shown in Fig. 4, the typical laddering of
200-base pair fragments was increased markedly for 30% confluent cells (lane 2, NG108-15; lane 4, F-11) compared with
cells with 100% confluence (lane 3, NG108-15; lane
5, F-11). The dependence of apoptosis on the cell cycle was
analyzed by detection of cyclin E using a specific antibody for
immunofluorescence microscopy. Apoptotic cells stained with Hoechst dye
or identified by terminal nucleotidyl transferase assay were
concomitantly immunoreactive with anti-cyclin E antibody, indicating an
onset of apoptosis at the G1 to S phase transition. The
apoptotic potential of C16-serinol in dependence on cell
differentiation was analyzed by incubation of undifferentiated PC12
cells and cells induced to differentiate by preincubation with 10 µM forskolin for 48 h. It was found that only
undifferentiated cells showed the typical staining with Hoechst dye
33258 after incubation with C16-serinol for 24 h.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Cell density-dependent rate of
apoptosis of NG108-15 cells on incubation with C16-serinol.
NG108-15 cells were grown to the degree of confluence (100% = 1.0 × 105 cells/cm2) as indicated and then
incubated overnight with 100 µM C16-serinol.The floating
cells were harvested from the medium and the amount of cellular protein
determined for calculation of dead cells. In addition, cell death was
quantified by staining with trypan blue. The attached cells were
stained with Hoechst dye 33258 for calculation of apoptotic cells with
condensed chromatin. The number of apoptotic cells was determined by
counting 100 stained cells in 20 different areas on tissue culture
dishes from three independent experiments.
|
|

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 4.
Cell density-dependent DNA
fragmentation of NG108-15 or F-11 cells upon incubation with
C16-serinol. NG108-15 or F-11 cells were grown to 30% (lane
2, NG108-15; lane 4, F-11) or 100% confluence
(lane 3, NG108-15; lane 5, F-11) and were
incubated overnight with 200 µM C16-serinol. The nuclear
DNA was extracted and analyzed by agarose gel electrophoresis followed
by staining with ethidium bromide. Lane 1, standard.
bp, base pairs.
|
|
The effect of the alkyl chain length on the apoptotic potential of
N-acylated serinols was evaluated by incubation of
neuroblastoma cells with C8- and C18-serinol compared with C16-serinol.
Furthermore, the contribution of the second -hydroxymethyl group of
C16-serinol was analyzed by comparison with the effect of C16-EA on
apoptosis. Fig. 5 shows the dependence of
cell death on the concentrations of the various effectors. Cell death
was monitored by determination of the number of floating and trypan
blue-stained cells and corresponded to the degree of staining of
adherent cells with Hoechst dye. The results indicated that there was
an optimal chain length of the alkyl residue in N-acylated
serinol for induction of apoptosis which roughly corresponded to that
of the palmitoyl residue. C8-serinol was of extremely low apoptotic
potential and that of C18-serinol was reduced by about 50% at a
concentration of 100 µM. In addition, there was almost no
apoptosis observable with C16-EA, indicating the significance of a
second -hydroxymethyl group in C16-serinol.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Apoptosis of neuroblastoma cells and
dependence on the alkyl chain length and number of
-hydroxy groups of N-acylated
amides. NG108-15 or F-11 cells were grown to 30% confluence and
incubated overnight with various concentrations of C8-serinol ( ),
C16-serinol ( ), C18-serinol ( ), or C16-EA ( ). The floating
cells were harvested from the medium and the amount of cellular protein
determined for calculation of dead cells. In addition, cell death was
quantified by staining with trypan blue. The attached cells were
stained with Hoechst dye 33258 for calculation of apoptotic cells with
condensed chromatin. The number of apoptotic cells was determined by
counting 100 stained cells in 20 different areas on tissue culture
dishes from three independent experiments.
|
|
Signal Pathways Involved in C16-Serinol-induced Apoptosis--
The
signal pathway by which C16-serinol may have affected ceramide-induced
apoptosis was evaluated by use of effectors antagonizing the apoptotic
signal cascade for ceramide. Simultaneous incubation with PMA, known to
counteract ceramide-induced apoptosis in chicken embryo astrocytes by
activation of PKC (27), only partially suppressed the apoptotic effects
of C16-serinol (less than 20% reduction of the number of apoptotic
cells). The different isoforms of PKC, including the classical PKC
(cPKC ) and as well as the novel isoenzymes (nPKC) were
specifically affected by the inhibitors Gö 6983, Gö 6976, and staurosporine. Novel PKC isoforms, in particular PKC , have been
shown to be modulated by binding to ceramide (28, 34). Its involvement
in C16-serinol-induced apoptosis was evaluated by inhibition with
Gö 6983 compared with Gö 6976 and staurosporine, two PKC
inhibitors that do not affect PKC . Only Gö 6983 suppressed
C16-serinol-induced apoptosis by about 70%. Inhibition with Gö
6976 and staurosporine resulted in an amplification of apoptosis.
Analysis of Protein Kinases Eluted from
C16-Serinol-Sepharose--
The binding specificity of C16-serinol was
analyzed by chromatography of protein solubilized from rat brain on
affinity gels containing the immobilized analog as ligand. As shown in
Fig. 6, protein eluted from
C16-serinol-Sepharose was characterized by SDS-PAGE and a potential
kinase activity determined by a gel activity assay. Elution with buffer
only (lane 1) showed only minute amounts of protein,
indicating the specificity of the elution with C16-serinol (lane
2). Characterization of the protein was attempted by a gel
activity assay for serine/threonine-specific protein kinases. The
activity was monitored by phosphorylation of myelin basic protein using
[ -32P]ATP as a substrate. The protein eluted from
C16-serinol-Sepharose contained at least three different protein
kinases with molecular masses of 50, 70, and 95 kDa (lane
3). The protein kinase species were analyzed further by
immunoblotting using a PKC -specific antibody for immunodetection. As
shown in lane 4, the protein kinase of 70 kDa was
immunostained, and the other protein kinase species were not identified
yet.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of rat brain protein
affinity-purified on C16-serinol-Sepharose. A solubilized protein
sample obtained with 0.5% Triton X-100 from 2 g of rat brain was
applied to 0.5 ml of C16-serinol-Sepharose as described under
"Experimental Procedures." After intensive washing with 100 volumes
of buffer, the gels were eluted with 2.0 ml of 0.5 mM
C16-serinol in washing buffer. The eluted protein was precipitated by
the Wessel-Flügge method and separated by SDS-PAGE. Protein
analysis was achieved by silver staining (lane 1, effluent
of C16-serinol-Sepharose with washing buffer; lane 2, eluate
with C16-serinol); lane 3, protein kinase-specific gel
activity assay; lane 4, immunoblotting using a
PKC -specific polyclonal antibody. Lanes 5 and
6, PKC autophosphorylation assay by labeling of F-11
cells with 32P without (lane 5) or with
(lane 6) prior incubation with C16-serinol.
|
|
The effect of C16-serinol on the activity of PKC was analyzed
in vitro using a peptide substrate as phosphate acceptor and by determination of PKC autophosphorylation in neuroblastoma cells.
The in vitro phosphorylation assay was performed with human recombinant PKC optionally activated by the addition of
phosphatidylserine to 180% of the activity determined without
phosphatidylserine. Incubation of phosphatidylserine-activated PKC
with 100 µM C16-serinol resulted in a slight reduction of
enzyme activity by about 20 ± 5%. The activity of PKC without
phosphatidylserine activation, however, was activated considerably by
C16-serinol to 130 ± 7% at a concentration of 100 µM and 165 ± 10% at 150 µM.
Intracellular activation of PKC was evaluated by the analysis of
autophosphorylation upon incubation of F-11 cells with 100 µM C16-serinol for 8 h. The cells were then
metabolically labeled with 32P, and after solubilization,
PKC was isolated by immunoprecipitation and analyzed by SDS-PAGE and
autoradiography. In Fig. 6, lanes 5 and 6, it is
shown that incubation with C16-serinol enhanced the amount of
phosphorylated PKC by about 50%, which is consistent with the
activation of the enzyme observed in the in vitro
phosphorylation assay.
 |
DISCUSSION |
The design and synthesis of N-acylated serinol as a new
ceramide analogs were based on the rationale to mimic the hydrophilic -hydroxyamide motif derived from serine and the hydrophobic
aliphatic moieties of the ceramide/sphingosine moiety. The effect of
the N-acyl chain length was analyzed by introduction of
different fatty acid residues ranging from C8 to C18. In particular,
C16-serinol was studied for its potential to serve as a substrate or an
inhibitor of enzymes involved in ceramide metabolism. An enzyme kinetic characterization, however, revealed that its affinity to
glucosyltransferase or lysosomal ceramidase was weak compared with ceramide.
The biological effects observed with different N-acylated
derivatives of serinol were evaluated by the analysis of cell growth and apoptosis in neuroblastoma cells. Incubation of NG108-15 or F-11
cells with C16-serinol elevated the concentration of endogenous ceramide to 150-180% of the value found in unaffected control cells
and eventually resulted in apoptotic cell death. Ceramide elevation may
have been caused by moderate inhibition of acid ceramidase. The effects
on other species of ceramidase have not been analyzed yet. However,
previous studies have reported a ceramide elevation by more than 2-fold
for induction of apoptosis in F-11 cells (8). Most recently, we have
found that induction of apoptosis in murine neuroblastoma cells by
incubation with PDMP was concomitant with an elevation of endogenous
ceramide by 3-4-fold (18). Thus, induction of apoptosis by C16-serinol
very likely involved an activity in addition to elevation of endogenous
ceramide. A putative mechanism underlying this additional activity of
C16-serinol could be given by direct binding of C16-serinol to target
proteins that are regulated by ceramide. This assumption is consistent
with the observation that the apoptotic potential of
N-acylated serinol was critically dependent on the chain
length of the fatty acid residue and was found to be maximal with
C16-serinol. Recently, we have reported that the major species of
ceramide elevated in apoptotic neuroblastoma cells was C16:0 ceramide
(18). In this species the lengths of the alkyl chain of sphingosine and
the fatty acid are very similar and may be functionally substituted by
a single N-acyl chain as given in C16-serinol for effective binding of ceramide target proteins (Fig. 1). Binding of
N-acylated serinol to sphingosine targets cannot be excluded
because the structural features necessary for the effectiveness of
C16-serinol may have also mimicked those found in sphingosine, which
has been reported to induce apoptosis by inhibition of PKC (3, 35). In
particular, the presence of a second -hydroxy group was
indispensable for apoptotic activity as demonstrated by the
ineffectiveness of C16-EA.
To analyze potential binding proteins C16-serinol was immobilized on a
Sepharose gel matrix and used for affinity chromatography of protein
solubilized from rat brain. Among the protein species eluted from
C16-serinol-Sepharose there were at least three different serine/threonine-specific protein kinases as determined by a gel activity assay. In particular, immunodetection of PKC in the C16-serinol-Sepharose eluate indicated that this protein kinase showed
considerable affinity to C16-serinol. Recently, it has been found that
modulation of PKC by binding to ceramide may be one trigger switch
for elicitation of apoptosis and other effects of tumor necrosis factor
(34, 36). Ceramide can also specifically activate another protein
kinase (ceramide-activated protein kinase) or phosphatase
(ceramide-activated protein phosphatase) (1, 5, 35-40). It is known
that stress factors or cytokines activate a protein kinase cascade
(stress-activated protein kinase) via ceramide released by plasma
membrane-bound neutral sphingomyelinase (1, 5, 35, 37). It has been
found that ceramide may act on PKC in a dual mode: activation in low
concentrations and inactivation at higher concentrations (28, 34). It
has been suggested that PKC activates Jun NH2-terminal
kinase and constitutes a critical switch for balancing cell survival
and cell death. It is very likely that C16-serinol exerts at least part
of its physiological activity by direct binding to PKC . This
assumption was corroborated by the results of an in vitro
phosphorylation assay revealing that PKC was activated by
C16-serinol. Activation of PKC was also indicated by enhanced
autophosphorylation of this enzyme in effector-incubated neuroblastoma
cells and by suppression of apoptosis by simultaneous incubation with
Gö 6983. The assumption that PKC participates in apoptosis by
a PKC-independent pathway is in line with the observation that PMA did
not suppress cell death upon induction with C16-serinol.
C16-serinol may thus be useful in evaluation of PKC -mediated signal
cascades and their importance for neuronal cell development. It should
be noted that more than half of the mitotic glia cells and neurons die
during fetal brain development by apoptosis (33, 41-43). The
observation that C16-serinol induces apoptosis only in rapidly dividing
neuroblastoma cells indicates an anti-cancer potential. It should be
noted that the spontaneous regression of astrocytoma tumors in young
children has been correlated with an apoptotic process in rapidly
dividing cells (33). Future studies will aim at an investigation of
further target proteins of C16-serinol to evaluate the mechanism for
ceramide-induced apoptosis and to develop anti-cancer strategies based
on this mechanism.
 |
ACKNOWLEDGEMENT |
We thank Dr. Minoru Suzuki (Medical College of
Virginia Campus of Virginia Commonwealth University, Richmond, VA) for
the FAB-mass spectrometrical analysis on a ZAB SE mass spectrometer (VG
Analytical, Manchester, U. K.).
 |
FOOTNOTES |
*
This study was supported by United States Public Health
Service Grant NS 11853 and an A. D. Williams grant.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biophysics, Medical College of Virginia Campus of
Virginia Commonwealth University, 1101 E. Marshall St., P. O. Box
980614, Richmond, VA 23298. Tel.: 804-828-9217; Fax: 804-828-1473; E-mail: ebieberi@hsc.vcu.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
PDMP, d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol;
d-erythro-MAPP, d-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol;
NOE, N-oleoylethanolamine;
C16-serinol, N-palmitoyl-2-amino-1,3-propanediol;
C16-EA, N-palmitoylethanolamine;
PMA, -phorbol 12-myristate
13-acetate;
PKC, protein kinase C;
HPTLC, high performance thin layer
chromatography;
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Ariga, T.,
Jarvis, W. D.,
and Yu, R. K.
(1998)
J. Lipid Res.
39,
1-16[Abstract/Free Full Text]
|
| 2.
|
Ballou, L. R.,
Laulederkind, S. J. F.,
Rosloniec, E. F.,
and Raghow, R.
(1996)
Biochim. Biophys. Acta
1301,
273-287[Medline]
[Order article via Infotrieve]
|
| 3.
|
Cuvillier, O.,
Pirianov, G.,
Kleuser, B.,
Vanek, P. G.,
Coso, O. A.,
Gutkind, J. S.,
and Spiegel, S.
(1996)
Nature
381,
800-803[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Hannun, Y. A.
(1996)
Science
274,
1855-1859[Abstract/Free Full Text]
|
| 5.
|
Hannun, Y. A.,
and Linardic, C. M.
(1993)
Biochim. Biophys. Acta
1154,
223-236[Medline]
[Order article via Infotrieve]
|
| 6.
|
Hannun, Y. A.,
and Obeid, L. M.
(1995)
Trends Biochem. Sci.
20,
73-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Obeid, L. M.,
and Hannun, Y. A.
(1995)
J. Cell. Biochem.
58,
191-198[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Wiesner, D. A.,
and Dawson, G.
(1996)
Glycoconj. J.
13,
327-333[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Ji, L.,
Zhang, G.,
Uematsu, S.,
Akahori, Y.,
and Hirabayashi, Y.
(1995)
FEBS Lett.
358,
211-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Mathias, S.,
Pena, L. A.,
and Kolesnick, R. N.
(1998)
Biochem. J.
335,
465-480
|
| 11.
|
Yu, R. K.
(1994)
Prog. Brain Res.
101,
31-44[Medline]
[Order article via Infotrieve]
|
| 12.
|
Abe, A.,
Radin, N. S.,
Shayman, J. A.,
Wotring, L. L.,
Zipkin, R. E.,
Sivakumar, R.,
Ruggieri, J. M.,
Garson, K. G.,
and Ganem, B.
(1995)
J. Lipid Res.
36,
611-621[Abstract]
|
| 13.
|
Arora, R. C.,
and Radin, N. S.
(1972)
J. Lipid Res.
13,
86-91[Abstract]
|
| 14.
|
Bielawska, A.,
Greenberg, M. S.,
Perry, D.,
Jayadev, S.,
Shayman, J. A.,
McKay, C.,
and Hannun, Y. A.
(1996)
J. Biol. Chem.
271,
12646-12654[Abstract/Free Full Text]
|
| 15.
|
Inokuchi, J.-I.,
and Radin, N. S.
(1987)
J. Lipid Res.
28,
565-571[Abstract]
|
| 16.
|
Vunnam, R. R.,
and Radin, N. S.
(1980)
Chem. Phys. Lipids
26,
265-278[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Platt, F. M.,
Neises, G. R.,
Dwek, R. A.,
and Butters, T. D.
(1994)
J. Biol. Chem.
269,
8362-8365[Abstract/Free Full Text]
|
| 18.
|
Bieberich, E.,
Freischütz, B.,
Suzuki, M.,
and Yu, R. K.
(1999)
J. Neurochem.
72,
1040-1049[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Freischütz, B.,
Tokuda, A.,
Ariga, T.,
Bermudez, A. J.,
and Yu, R. K.
(1997)
J. Neurochem.
68,
2070-2078[Medline]
[Order article via Infotrieve]
|
| 20.
|
Fewster, M. E.,
Burns, B. J.,
and Mead, J. F.
(1969)
J. Chromatogr.
43,
120-126[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Macala, L. J., Yu, R. K.,
and Ando, S.
(1983)
J. Lipid Res.
25,
1243-1250
|
| 22.
|
Ryu, E. K.,
and MacCoss, M.
(1979)
J. Lipid Res.
20,
561-563[Abstract]
|
| 23.
|
Svennerholm, L.
(1957)
Biochim. Biophys. Acta
24,
604-611[Medline]
[Order article via Infotrieve]
|
| 24.
|
Kameshita, I.,
and Fujisawa, H.
(1989)
Anal. Biochem.
183,
139-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Kapitonov, D.,
and Yu, R. K.
(1997)
Biochem. Biophys. Res. Commun.
232,
449-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Bernardo, K.,
Hurwitz, R.,
Zenk, T.,
Desnick, R. J.,
Ferlinz, K.,
Schuchman, E. H.,
and Sandhoff, K.
(1995)
J. Biol. Chem.
270,
11098-11102[Abstract/Free Full Text]
|
| 27.
|
Mangoura, D.,
and Dawson, G.
(1998)
J. Neurochem.
70,
130-138[Medline]
[Order article via Infotrieve]
|
| 28.
|
Wang, Y. M.,
Seibenhener, M. L.,
Vandenplas, M. L.,
and Wooten, M. W.
(1999)
J. Neurosci. Res.
55,
293-302[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Wang, C.-S.,
and Smith, R. L.
(1975)
Anal. Biochem.
63,
414-417[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Wessel, D.,
and Flügge, U. I.
(1984)
Anal. Biochem.
138,
141-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Gershoni, J. M.,
and Palade, G. E.
(1983)
Anal. Biochem.
131,
1-15[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Schwab, M.
(1999)
Naturwissenschaften
86,
71-78[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Müller, G.,
Ayoub, M.,
Storz, P.,
Rennecke, J.,
Fabbro, D.,
and Pfizenmaier, K.
(1995)
EMBO J.
14,
1961-1969[Medline]
[Order article via Infotrieve]
|
| 35.
|
Jarvis, W. D.,
Kolesnick, R. N.,
Fornari, F. A.,
Traylor, R. S.,
Gewirtz, D. A.,
and Grant, S.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
73-77[Abstract/Free Full Text]
|
| 36.
|
Mathias, S.,
Dressler, K. A.,
and Kolesnick, R. N.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
10009-10013[Abstract/Free Full Text]
|
| 37.
|
Haimovitz-Friedman, A.,
Kolesnick, R. N.,
and Fuks, Z.
(1997)
Br. Med. Bull.
53,
539-553[Abstract/Free Full Text]
|
| 38.
|
Dobrowsky, R. T.,
and Hannun, Y. A.
(1992)
J. Biol. Chem.
267,
5048-5051[Abstract/Free Full Text]
|
| 39.
|
Galadari, S.,
Kishikawa, K.,
Kamibayashi, C.,
Mumby, M. C.,
and Hannun, Y.
(1998)
Biochemistry
37,
11232-11238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Liu, J.,
Mathias, S.,
Yang, Z.,
and Kolesnick, R.
(1994)
J. Biol. Chem.
269,
3047-3052[Abstract/Free Full Text]
|
| 41.
|
Krueger, B. K.,
Burne, J. F.,
and Raff, M. C.
(1995)
J. Neurosci.
15,
3366-3374[Abstract]
|
| 42.
|
Milligan, C.,
and Schwartz, L. M.
(1997)
Br. Med. Bull.
52,
570-590
|
| 43.
|
Oppenheim, R.
(1991)
Annu. Rev. Neurosci.
14,
453-501[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Wang, K. Krishnamurthy, N. S. Umapathy, A. D. Verin, and E. Bieberich
The Carboxyl-terminal Domain of Atypical Protein Kinase C{zeta} Binds to Ceramide and Regulates Junction Formation in Epithelial Cells
J. Biol. Chem.,
May 22, 2009;
284(21):
14469 - 14475.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Krishnamurthy, G. Wang, J. Silva, B. G. Condie, and E. Bieberich
Ceramide Regulates Atypical PKC{zeta}/{lambda}-mediated Cell Polarity in Primitive Ectoderm Cells: A NOVEL FUNCTION OF SPHINGOLIPIDS IN MORPHOGENESIS
J. Biol. Chem.,
February 2, 2007;
282(5):
3379 - 3390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Senkal, S. Ponnusamy, M. J. Rossi, K. Sundararaj, Z. Szulc, J. Bielawski, A. Bielawska, M. Meyer, B. Cobanoglu, S. Koybasi, et al.
Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo
J. Pharmacol. Exp. Ther.,
June 1, 2006;
317(3):
1188 - 1199.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Van Overloop, S. Gijsbers,, and P. P. Van Veldhoven
Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies
J. Lipid Res.,
February 1, 2006;
47(2):
268 - 283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wang, J. Silva, K. Krishnamurthy, E. Tran, B. G. Condie, and E. Bieberich
Direct Binding to Ceramide Activates Protein Kinase C{zeta} before the Formation of a Pro-apoptotic Complex with PAR-4 in Differentiating Stem Cells
J. Biol. Chem.,
July 15, 2005;
280(28):
26415 - 26424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bieberich, J. Silva, G. Wang, K. Krishnamurthy, and B. G. Condie
Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants
J. Cell Biol.,
November 22, 2004;
167(4):
723 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Chalfant, Z. Szulc, P. Roddy, A. Bielawska, and Y. A. Hannun
The structural requirements for ceramide activation of serine-threonine protein phosphatases
J. Lipid Res.,
March 1, 2004;
45(3):
496 - 506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Powell, E. Hajduch, G. Kular, and H. S. Hundal
Ceramide Disables 3-Phosphoinositide Binding to the Pleckstrin Homology Domain of Protein Kinase B (PKB)/Akt by a PKC{zeta}-Dependent Mechanism
Mol. Cell. Biol.,
November 1, 2003;
23(21):
7794 - 7808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Bourbon, L. Sandirasegarane, and M. Kester
Ceramide-induced Inhibition of Akt Is Mediated through Protein Kinase Czeta . IMPLICATIONS FOR GROWTH ARREST
J. Biol. Chem.,
January 25, 2002;
277(5):
3286 - 3292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shizukuda and P. M. Buttrick
Protein kinase C-zeta modulates thromboxane A2-mediated apoptosis in adult ventricular myocytes via Akt
Am J Physiol Heart Circ Physiol,
January 1, 2002;
282(1):
H320 - H327.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. J. Chae, S. W. Chae, J. S. Kang, B. G. Bang, S. B. Cho, R. K. Park, H. S. So, Y. K. Kim, H. M. Kim, and H. R. Kim
Dexamethasone Suppresses Tumor Necrosis Factor-{alpha}-Induced Apoptosis in Osteoblasts: Possible Role for Ceramide
Endocrinology,
August 1, 2000;
141(8):
2904 - 2913.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Bourbon, J. Yun, and M. Kester
Ceramide Directly Activates Protein Kinase C zeta to Regulate a Stress-activated Protein Kinase Signaling Complex
J. Biol. Chem.,
November 3, 2000;
275(45):
35617 - 35623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bieberich, S. MacKinnon, J. Silva, and R. K. Yu
Regulation of Apoptosis during Neuronal Differentiation by Ceramide and b-Series Complex Gangliosides
J. Biol. Chem.,
November 21, 2001;
276(48):
44396 - 44404.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|